Delilah Alvarado

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from respiratory syncytial virus.

While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.

Every presidential election brings change to the Food and Drug Administration. This time around, the upheaval could be particularly jarring.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

The regulator said monitoring data following the vaccines' approvals suggest an elevated risk of Guillan-Barré syndrome, but didn't establish a causal link.

The results suggest Bayer's elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with menopause as well as a common breast cancer therapy.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Moderna lost more than $3 billion in maker value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.

Security was tight for the first day of the J.P. Morgan Healthcare Conference, which featured major M&A as well as presentations from several large pharma companies.